Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

← catalyst calendar

NCT07154823 · readout ≤ 3,025 d

Sponsored by Tempus AI (industry) · TEM — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
550estimated
Sites
9
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-01-27actualWhen the study began enrolling
Primary completionNov 2034estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionNov 2035estimatedThe whole study's end, after follow-up
First posted2025-09-04actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-21actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Acute Myeloid Leukaemia (AML)
  • Follicular Lymphoma ( FL)

Intervention

  • Other: None - Observational Study

Primary outcome

what the primary-completion date above is the date OF
To assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications.
measured 5 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed